On Sept. 1, 2022, Novavax announced that Nuvaxovidﾙ (NVX-CoV2373) COVID-19 vaccine had been recommended for expanded conditional marketing authorization (CMA) in the European Union (EU) as a homologous and heterologous booster for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for adults aged 18 and older.